top of page
Strategic Advising
Where clinical and strategic experience support meaningful work in healthcare
ClearPoints Advisory, LLC
Dr Lamberth has over 21 years as a practicing physician who discussed vaccines with parents and patients on a daily basis, 18 years as a site investigator for numerous currently licensed vaccines and over 16 years as an IRB chair, overseeing approximately 35 concurrent clinical trials in oncology, cardiology, and vaccines.
Experience at Pfizer as a Global Program Lead, Clinical Lead or Clinician for pediatric and adult clinical trials spanning Phases 1-3 in the Pneumococcal, Covid-19, C. difficile, RSV, Lyme and Meningococcal programs.
Dr Lamberth holds the position of Associate Scholar at the Center for Clinical Epidemiology and Biostatistics at the Perelman School of Medicine at the University of Pennsylvania, and has held previous academic appointments at Temple University School of Medicine and Haverford College.
Collaborators:
Publications
Gretchen Cook, Erik Lamberth, Stephen Lockhart, Francine Lowry, Haiying Zhang, Yahong Peng, Kenneth Korey, Warren Karina, Michael Pride, Annaliessa Anderson, William Gruber, Nicholas Kitchen. Randomized Phase 3 Comparison of a 2-Dose and 3-Dose Regimen of a Detoxified Toxin A/B Clostridioides difficile Vaccine in Adults 50 Years and Older. Open Forum Infectious Diseases, May 2026 13(5)
Raphael Simon, Erik Lamberth, James Stark, Julie Skinner, A Human Lyme Disease Vaccine: two steps forward on a path to prevention. Expert Review of Vaccines 2025 Dec; 25(1):2607482
Marc Messier, James Stark, Laura Wagner, Erik Lamberth, Antibody response and safety through 12 months after booster vaccination with an investigational Lyme disease vaccine in adults; a plain language summary, Current Medical Research Opinion Sept 2025; 41(9):1753-1762
Federico Martinon-Torres, Erik Lamberth, et al, Safety, tolerability and immunogenicity of a pentavalent meningococcal MenABCWY vaccine in healthy infants: A phase 2b randomized clinical trial, Human Vaccines & Immunotherapeutics, Feb 2025; 211, 2463194
Marc Messier, Laura Wagner, Erik Lamberth, et al, 6-Valent OspA-Based VLA15 Lyme Disease Vaccine Candidate Against Lyme Borreliosis in a Healthy Pediatric and Adult Study Population: A Phase 2 Study Update, Open Forum Infectious Diseases, Jan 2025 12. 10.1093/ofid/ofae631.797
Curtis Donsky, Erik R Dubberkke, Nicola Klein, Elizabeth Liles, Katarzyna Szymkowiak, Mark Wilcox, Jody Lawrence, Salim Bouguermouh, Haiying Zhang, Ruth bailey, Helen Smith, Stephen Lockhart, Erik Lamberth, Warren V Kalina, Michael W Pride, Chris Webber, Kathrin U Jansen, William Gruber, Nicholas Kitchin, CLOVER: A Phase 3 Randomized Trial Investigating the Efficacy and Safety of a Detoxified Toxin A/B Vaccine in Adults 50 Years and Older at Increased Risk of Clostridioides difficile Infection, August 2024, Clinical Infectious Diseases, 79(6) 79.10.1093/cid/ciae410
Shane Christiensen, Salim Bouguermouh, Kumar Ilangovan, Michael Pride, Chris Webber, Stephen Lockhart, Rupal Shah, Nicholas Kitchin, Erik Lamberth, Haiying Zhang, Qi Gao, Linda Brock, Annaliesa Anderson, William Gruber, A phase 3 study evaluating the lot consistency, immunogenicity, safety, and tolerability of a Clostridioides difficile vaccine in healthy adults 65 to 85 years of age. Nov 2023, Vaccine 41(50) 41.10.1016/j.vaccine.2023.11.003
Michael Simon, Regine Bataille, Nicole Caldwell, Bradford Gessner, Luis Jodar, Erik Lamberth, Yahong Peng, Daniel Scott, Lanyu Lei, Peter Giardina, William Griuber, Kathrin U Jansen, Allison Thompson, Wendy Watson, Safety and immunogenicity of a multivalent pneumococcal conjugate vaccine given with 13-valent pneumococcal conjugate vaccine in healthy infants: A phase 2 randomized trial, Aug 2023, Human Vaccines & immunotherapeutics, 19(2):2245727
Shelly Senders, Nicola Klein, Erik Lamberth, et al, Safety and Immunogenicity of a 20-Valent Pneumococcal Conjugate Vaccine (PCV20) in Healthy Infants in the United States, Open Forum Infectious Diseases 7 December 2020, (Supplement_1):S637-S637
Shelly Senders, Nicola Klein, Erik Lamberth, et al, Safety and Immunogenicity of a 20-valent Pneumococcal Conjugate Vaccine in Healthy Infants in the United States, Oct 2021 The Pediatric Infectious Disease Journal, 40(10):944-951
Allison Thompson, Erik Lamberth, et al, Phase 1 trial of a 20-valent pneumococcal conjugate vaccine in healthy adults. Vaccine 2019 Sep 30;37(42):6201-6207
Lamberth, E. F., Rothstein, E. P., Hipp, T. J., Souder, R. L., Kennedy, T. I., Faccenda, D. F., et al. Rates of missed appointments among pediatric patients in a private practice: Medicaid compared with private insurance. Archives of Pediatrics and Adolescent Medicine 2002; 156(1) 86-87
Invited Talks
Efficacy and Safety of Clostridioides difficile vaccine in Adults ³50 Years Old: Results From the CLOVER Trial, World Vaccine Congress, Washington, DC, April, 2024
Poster Presentations
Marc Messier, Laura Wagner, Romaina Hochreiter, Erik Lamberth, Julian Larcher-Senn, Raphael Simon, James Groark, James Start. 6-Valent OspA-Based VLA-15 Lyme Disease Vaccine Candidate Against Lyme Borreliosis in a Healthy Pediatric and Adult Study population: A Phase 2 Study Update, ID Week, Los Angeles CA, October, 2024
Shelly Senders, Nicola Klein, Erik Lamberth, Allison Thompson, Jelena Drozd, James Trammel, Yahong Peng, Peter C. Giardina, Kathrin U. Jansen, William C. Gruber, Daniel Scott, Wendy Watson. Safety and Immunogenicity 20-Valent Pneumococcal Conjugate Vaccine (PCV20) in Healthy Infants in the United States, ID Week, October 2020
Erik Lamberth, Ed Rothstein, Tom Hipp, Ronald Souder, Tom Kennedy, Deborah Faccenda, Danielle Casher, Richard Kratz, Barbara Homeier. Rates of missed appointments among pediatric patients in a private practice, Pediatric Academic Society, Baltimore, MD, 2002
bottom of page